



Tanvex entering into service contract with OBI

June 20, 2021

Tanvex BioPharma, Inc. (TWSE 6541) announces that it has entered into a service contract with OBI Pharma for the development of a novel antibody drug. Tanvex will be responsible for the cell line development and will leverage its expertise on ensuring the robustness of the cell-line for manufacturing. “With the establishment of our vertically integrated Tanvex platform, we can maximize the strategic flexibility for Tanvex by expanding to new drug development. We are looking forward to working with OBI over the long term.” said Lin-Cheng (Henry) Chen, Chairman and Chief Executive Officer of Tanvex BioPharma.

About Tanvex

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.